



## Abstract Guidelines

Academics, researchers, industry, government agencies, healthcare professionals, patient organizations, and other interested parties, such as students that have conducted rare disease or orphan product research studies or public health projects relevant in glycoproteinoses rare disease research. All are invited to submit an abstract for inclusion in the poster hall at **The ISMRD 7th International Glycoproteinoses Conference August 7-10, 2025** in Minneapolis, MN.

The ISMRD Scientific Advisory Committee is interested in abstracts that highlight new research, change clinical practice, enhance patient care, or increase patient engagement or patient advocacy. The four (4) categories listed below are the focus areas for the event. Please use these as a guide as you develop your abstract for consideration of inclusion in The ISMRD 7th International Glycoproteinoses Conference Poster Hall.

## Categories

### 1. Innovative Research in Glycoproteinoses Rare Diseases and Orphan Products

Abstracts to cover projects relevant in glycoproteinoses rare diseases, innovative or orphan products research, including preclinical models, clinical studies, case studies, patient-focused studies, technological, economic, or policy research as it relates to health and social issues. Also included in this theme are collaborative initiatives and centers of excellence that involve ground-breaking strategies or projects that could be useful to other groups, organizations, patients, government, academics or professionals in the rare disease and orphan product community.

### 2. Medical Education Advancement in Glycoproteinoses Rare Diseases and Orphan Products

Abstracts to cover public health awareness and education of healthcare professionals (HCPs); information exchange or training that leads to advancements in screening and/or diagnosis; or innovative models for medical education training.

### 3. Patient Community Building in Glycoproteinoses Rare Diseases

Abstracts to cover topics such as advancements in patient education; novel ways to increase patient engagement in the rare disease community; or successful models in increasing patient advocacy and awareness by leveraging technology or communications channels.

#### 4. Other Topics relevant to Glycoproteinoses Rare Diseases

These abstracts should still relate to the overall topic of glycoproteinoses rare diseases and orphan products but do not fit within the themes previously listed.

### Eligibility

You may submit poster abstracts under one of the two submission groupings below:

#### 1. Student (graduate or undergraduate)

Individuals submitting an abstract under the Student category must be an undergraduate or graduate student enrolled in a Bachelor's, Master's, PharmD, MD, DVM, or PhD (or equivalent) academic program at an accredited academic institution. Individuals must be able to provide documentation of this enrollment upon request.

The submitted research must have been conducted at an academic institution.

Individuals who completed a degree during the 2025 academic year may submit a student poster only if they are able to provide documentation that they were an eligible student at the time the research was conducted.

**2. Professional** (post-doctoral scholars, medical residents/fellows/professionals, patient advocates/advocacy groups, government agencies and manufacturers.)

### Key Dates

Submission deadline via <a href="#">submission form</a>	<b>April 30, 2025</b>
ISMRD Scientific Advisory Committee notifies authors of acceptance	<b>May 20, 2025</b>
Registration deadline for accepted Abstract attendees	<b>June 20, 2025</b>
Deadline for Digital posters for Accepted Abstracts Attendees.	<b>July 15, 2025</b>
<i>Digital posters sent after this date are not guaranteed to be included on the event app</i>	
Accepted Attendees set up Posters in Poster Hall	<b>August 7, 2025</b>

### General Requirements & Guidelines

1. All abstracts must be submitted by April 30, 2025, with no exceptions. Abstracts will only be accepted via this [form](#).
2. Abstracts should be noncommercial. Generic names of drugs should be used throughout the abstract.
3. Posters should include data for consideration. Preliminary and pilot data will be accepted.
4. Abstracts should be original in research, include appropriate empirical evidence, and not have been widely presented or circulated prior to The ISMRD 7th International Glycoproteinoses Conference.

5. Encore abstracts are welcome if the work does not infringe upon any copyright, proprietary or personal right of any third party and so long as the data has been updated.
6. Copyright issues: Authors who use resources that are not their own (pictures, charts, graphs, etc.) in their abstract must cite the original source. If authors draw heavily on another source, it is the author(s)'s responsibility to seek and receive permission to use the material.
7. Use of data accepted and/or published as a journal article: Data accepted or published by a medical or academic journal may be used if it is cited and does not infringe on any copyright issues with the journal. It is the author(s)' responsibility to seek and receive permission to use the data.
8. Referral to webpages or URLs may not be used in the abstract.
9. Author(s) may not submit the same abstract under more than one category. Duplicate submissions will not be accepted.
10. Author(s) may not present more than three abstracts during The ISMRD 7th International Glycoproteinoses Conference, and each abstract must be different.
11. Submission of an abstract constitutes a commitment by the presenting author to present their work in person at The ISMRD 7th International Glycoproteinoses Conference Poster Hall if the abstract is accepted.

## Format

Abstracts should be **no more than one page**, excluding space for tables and figures, and utilize the following specifications:

- Minimum font size 11
- Single-spaced rows
- One-inch margins

**Abstracts should be organized as follows:**

- **Title of Abstract**
- **Authors, Institution, and Institution Location** (City, State or Province, and Country)  
Provide all authors' names in the order in which they should be listed.  
Presenting author to be designated prior to submission
- **Purpose:** Rationale of the study and/or the question addressed
- **Background:** Brief context around your study topic and why it is important
- **Methods:** Experimental approach, materials, and methods used in the study
- **Results:** Data and results obtained in the study
- **Conclusions:** Conclusions and/or implications of the results

***All poster abstracts must be noncommercial and without inclusion of trade names or logo by any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Any mention of specific products or and/or services must be limited to generic names, with no inclusion of trade names in any area of the poster, including poster titles.***

**Abstracts that do not follow this format and/or exceed one page will not be reviewed and considered for inclusion in The ISMRD 7th International Glycoproteinoses Conference poster hall.**

## Notification

Abstracts will be evaluated by ISMRD's Scientific Advisory Committee. The main contact for each abstract will be notified by ISMRD Scientific Advisory Committee staff about acceptance or nonacceptance **on May 20, 2025**. If an abstract is accepted, the main contact will be provided with additional information about the poster presentation format and requirements.

Notification and all correspondence will be with the main point of contact and additional contacts noted on the submission form.

## Accepted Abstracts

- As stated above, the submission of an abstract constitutes a commitment by the presenting author to present their work in the poster hall if the abstract is accepted. All additional abstract authors are encouraged to purchase a registration to attend the Conference. If the original designated presenting author is unable to attend, a co-author may be designated as an alternate presenter.

- Authors of accepted abstracts will prepare a physical poster for The ISMRD 7th International Glycoproteinoses Conference Poster Hall, as well as a PDF version for the Conference app.

- Embargo Policy: If your abstract is accepted, ISMRD asks that your poster not be shared publicly before the start of The ISMRD 7th International Glycoproteinoses Conference on August 7, 2025.

- ISMRD does not assign nor retain copyright on posters submitted for The ISMRD 7th International Glycoproteinoses Conference. Therefore, any permission to reuse materials after The ISMRD 7th International Glycoproteinoses Conference should be approved by the authors directly.

- Accepted abstracts may be shared on ISMRD's website for 2 years.

Questions: Please email [info@ismrd.org](mailto:info@ismrd.org)